A number of recent events such as a new worldwide wave of COVID-19, natural disasters in China and Germany, a cyber attack targeting key South African ports have conspired to drive global supply chains towards breaking point, threatening the fragile flow of raw materials, parts and consumer goods, according to companies, economists and shipping specialists.
The Delta variant of the coronavirus has devastated parts of Asia and prompted many nations to cut off land access for sailors. That’s left captains unable to rotate weary crews and about 100,000 seafarers stranded at sea beyond their stints in a flashback to 2020 and the height of lockdowns.
Vessel capacity is very tight, empty containers are scarce and the operational situation at certain ports and terminals is not really improving. Meanwhile, deadly floods in economic giants China and Germany have further ruptured global supply lines that had yet to recover from the first wave of the pandemic, compromising trillions of dollars of economic activity that rely on them.
In Germany, road transportation of goods has slowed significantly. In the week of July 11, as the disaster unfolded, the volume of late shipments rose by 15% from the week before, according to data from supply-chain tracking platform FourKites.
Ports across the globe are suffering the kinds of logjams not seen in decades, according to industry players. The China Port and Harbour Association said on Wednesday that freight capacity continued to be tight. A cyber attack hit South African container ports in Cape Town and Durban this week, adding further disruptions at the terminals.
Global vaccinations of seafarers are going too slowly to prevent outbreaks on ships from causing more trade disruptions, endangering maritime workers and potentially slowing economies trying to pull out of pandemic slowdowns.
For parts of the world where they are aiming to eliminate Covid, loopholes including maritime workers at container ports, are opportunities for the virus to break through,. They have to eliminate the risk coming off container ships. And if the risk to seafarers isn’t eliminated, then further port shutdowns and global supply disruptions are expected to be continued…
Read more at:
In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.
The global pharmaceutical fine chemicals sector is undergoing a profound transformation, with India emerging as a central growth engine amid sweeping changes in supply chain strategies and regulatory priorities. As drug makers and contract manufacturers adapt to stricter oversight and evolving sourcing preferences, the industry’s focus is shifting rapidly from cost efficiency to compliance, localisation and technical sophistication.
Stakeholders are being encouraged to weigh in on the European Chemicals Agency (ECHA) 60-day public consultation period related to a planned ban on per-and-polyfluoroalkyl (PFAS) substances, also known as forever chemicals.
We’re pleased to share an important milestone in our sustainability journey.
ExSyn has been awarded the EcoVadis Platinum Medal, placing us among the top 1% of companies globally evaluated for environmental, social and ethical performance.
While fears around a complete shutdown of the Strait of Hormuz primarily raise concerns around oil prices and energy security, recent history shows that even partial disruptions or security threats along key sea routes can quickly spill over into freight inflation, longer transit times and working capital stress for exporters and importers.
The European Union (EU) has agreed to offer Indian pharmaceutical and medical devices companies preferential access to EU market, along with cutting tariffs on 97.5 percent of chemical products to zero.
As we approach the close of this year, we at ExSyn would like to extend our heartfelt gratitude for your trust, collaboration, and continued support. Your confidence in our products and services has been the driving force behind our growth and success.
The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.
Products containing titanium dioxide in the EU are no longer required to carry warnings about cancer risk, after the European Chemicals Agency (Echa) revoked its classification as a suspected carcinogen. The move follows a June 2025 decision by the Court of Justice of the European Union and means that safety data sheets, labelling and packaging requirements for titanium dioxide have been relaxed across industries including paints, pharmaceuticals, cosmetics and food.